{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.163","value":"-3.01"},{"groupId":"OG001","spread":"3.093","value":"-5.49"},{"groupId":"OG002","spread":"3.277","value":"2.06"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"Bladder Voiding Efficiency (BVE) is a product of bladder contractility against the urethral resistance and is measured according to the degree of bladder emptying. BVE is expressed as a percentage and is calculated using the formula:\n\nBladder Voiding efficiency = (Voided volume x 100)/maximum cystometric capacity.\n\nA higher number indicates a higher voiding efficiency. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at Baseline \\& 1 or both at any postbaseline on-treatment visit. Data include the last on-treatment assessment for patients who did not complete the Week 12 visit.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 12","title":"Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE)","type":"SECONDARY","unitOfMeasure":"Percent voiding efficiency"}